Not Yet RecruitingNot Applicable

Abuse Liability for Eight Electronic Nicotine Products

70 participantsStarted 2026-02-15

Plain-language summary

This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \[PD\]), and plasma nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.

Who can participate

Age range21 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of the Principal Investigator (PI).
✓. Dual user of cigarettes and ENDS who self-reports:

What they're measuring

AUECPL 3-240

Timeframe: 3 minutes to 240 minutes

Emax PL

Timeframe: 240 minutes

Trial details

NCT IDNCT07323511

SponsorRAI Services Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04-15

Contact for this trial

Emily Smith

3356-741-2396 smithe13@rjrt.com

View on ClinicalTrials.gov More Smoking trials